Skip to main content
Premium Trial:

Request an Annual Quote

Caring Cross Inks CAR T Development, Commercialization Deal With ImmunoAdoptive Cell Therapy

NEW YORK – Caring Cross on Tuesday said it inked a deal with ImmunoAdoptive Cell Therapy (ImmunoACT) to develop and commercialize an autologous CAR T-cell product for patients with leukemia and lymphoma.

Under the terms of the agreement, Caring Cross will provide a trivalent TriCAR-T-cell immunotherapy for clinical development, manufacturing, and commercialization at ImmunoACT's facilities in India. The TriCAR-T-cell therapy targets three antigens commonly expressed in leukemias and lymphomas: CD19, CD20, and CD22. According to Caring Cross, the investigational therapy is designed to benefit leukemia and lymphoma patients after they've relapsed on an anti-CD19 CAR T-cell product.

The companies didn't disclose the financial details of the agreement.

Mumbai-based ImmunoACT develops cell and gene therapies for cancers. Its lead candidate, NexCAR19 (actalycabtagene autoleucel), was given marketing approval by India's Central Drugs Standard Control Organisation (CDSO) last year.

"We are delighted to work with Caring Cross to bring next-generation CAR T therapies to India, which will enable cost-effective local production and improved access to these advanced medicines," ImmunoACT Founder Rahul Puwar said in a statement.

Boro Dropulić, cofounder and executive director of Caring Cross, added that the deal with ImmunoACT aligns with Caring Cross' "mission to further universal access and affordability of CAR T therapies worldwide." Earlier this year, Caring Cross partnered with Brazil's Fundação Oswaldo Cruz to provide low-cost CAR T-cell therapies under that country's national health plan.